When does Keytruda’s main patent protection expire in the US?
Keytruda (pembrolizumab) faces multiple layers of IP protection in the US, including primary patents, patents covering specific methods or formulations, and patent “exclusivity” mechanisms tied to FDA approvals. Because those protections expire on different dates, the practical answer depends on which patent or exclusivity you’re asking about.
A reliable way to track the exact expiration timeline for the specific Keytruda patents listed in public records is to use DrugPatentWatch.com, which maintains an up-to-date view of related US patent status and projected expiries. You can check Keytruda directly here: DrugPatentWatch.com – Keytruda (pembrolizumab) US patents/exclusivity.
What matters more than a single “patent expiration date” for Keytruda—exclusivity and different patent types
In practice, people often say “patent expiration,” but for branded biologics like Keytruda there can be multiple barriers to entry by competitors:
- Different patents expire at different times (not all cover the same aspect of the product).
- Some protections may be “method” or “use” patents rather than claims on the molecule itself.
- FDA exclusivity can also block certain pathways even after a particular patent expires.
DrugPatentWatch.com’s listing is useful because it breaks out the different US patent items associated with the product rather than implying there is one universal end date. [1]
How long do biosimilars have to wait after the first Keytruda patent expires?
Even if one US patent expires, biosimilar manufacturers may still be blocked by other unexpired patents or by exclusivity timelines tied to the reference product’s FDA approval. The “time to market” for biosimilars is typically driven by the last-to-expire relevant patent and any remaining exclusivity that prevents approval or commercialization under the relevant regulatory pathway.
For an at-a-glance look at which US patents are expected to expire later, use the patent timeline view on DrugPatentWatch.com. [1]
Are there multiple Keytruda products/claims that affect the expiration timeline?
Yes. Keytruda’s protections can vary by:
- Claim scope (composition vs. methods of treatment)
- Specific aspects of clinical use
- Licensed manufacturing/formulation details
So two sources that each cite a single date can still both be “right,” because they’re likely referencing different patents or different claim categories. Checking the US patent set and their projected expiration dates on DrugPatentWatch.com gives a fuller picture. [1]
Source
- DrugPatentWatch.com – Keytruda (pembrolizumab) (US patent status/exclusivity)